HomeCompareGENPF vs EQR

GENPF vs EQR: Dividend Comparison 2026

GENPF yields 14184.40% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GENPF wins by $1741245461664930048.00M in total portfolio value
10 years
GENPF
GENPF
● Live price
14184.40%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1741245461664930048.00M
Annual income
$1,717,427,461,345,424,000,000,000.00
Full GENPF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — GENPF vs EQR

📍 GENPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGENPFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GENPF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GENPF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GENPF
Annual income on $10K today (after 15% tax)
$1,205,673.76/yr
After 10yr DRIP, annual income (after tax)
$1,459,813,342,143,610,500,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, GENPF beats the other by $1,459,813,342,143,610,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GENPF + EQR for your $10,000?

GENPF: 50%EQR: 50%
100% EQR50/50100% GENPF
Portfolio after 10yr
$870622730832465024.00M
Annual income
$858,713,730,672,712,000,000,000.00/yr
Blended yield
98.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

GENPF
No analyst data
Altman Z
-559.1
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GENPF buys
0
EQR buys
0
No recent congressional trades found for GENPF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGENPFEQR
Forward yield14184.40%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1741245461664930048.00M$40.5K
Annual income after 10y$1,717,427,461,345,424,000,000,000.00$3,819.61
Total dividends collected$1739668430966621440.00M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GENPF vs EQR ($10,000, DRIP)

YearGENPF PortfolioGENPF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$1,429,140$1,418,439.72$11,248$547.57+$1.42MGENPF
2$190,982,313$189,453,134.00$12,701$666.53+$190.97MGENPF
3$23,865,535,334$23,661,184,258.31$14,405$814.59+$23865.52MGENPF
4$2,788,853,260,935$2,763,317,138,127.58$16,413$999.84+$2788853.24MGENPF
5$304,771,704,176,462$301,787,631,187,262.06$18,795$1,232.92+$304771704.16MGENPF
6$31,148,518,911,483,350$30,822,413,188,014,540.00$21,639$1,527.95+$31148518911.46MGENPF
7$2,977,381,874,110,252,500$2,944,052,958,874,965,500.00$25,057$1,903.80+$2977381874110.23MGENPF
8$266,187,755,143,456,800,000$263,001,956,538,158,780,000.00$29,197$2,385.87+$266187755143456.75MGENPF
9$22,259,813,382,715,685,000,000$21,974,992,484,712,187,000,000.00$34,250$3,008.70+$22259813382715684.00MGENPF
10$1,741,245,461,664,930,200,000,000$1,717,427,461,345,424,000,000,000.00$40,467$3,819.61+$1741245461664930048.00MGENPF

GENPF vs EQR: Complete Analysis 2026

GENPFStock

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

Full GENPF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this GENPF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GENPF vs SCHDGENPF vs JEPIGENPF vs OGENPF vs KOGENPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.